BlachyJavierDávila SaldañaMD
Pediatric Hematology & Oncology • Washington, DCPediatric Hematologic Oncology
Director, Immunometabolic Bone Marrow Transplant Program
Dr. Dávila Saldaña is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Michigan Ave NW
Washington, DC 20010Phone+1 202-476-6900Fax+1 202-476-2280
Summary
- Dr. Blachy Dávila Saldaña is a pediatric hematologist/oncologist in Washington, DC and is affiliated with Children's National Hospital. He received his medical degree from University of Puerto Rico School of Medicine and has been in practice 10 years. He also speaks multiple languages, including Italian and Spanish. He specializes in pediatric hematologic oncology and is experienced in primary immunodeficiency diseases, bone marrow failure syndromes, pediatric bone marrow transplantation, and pediatric hematopoietic stem cell transplantation. He has more than 40 publications and over 500 citings.
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Allergy and Immunology, 2014 - 2015
Oregon Health & Science University (OHSU Health)Fellowship, Pediatric Hematology/Oncology, 2011 - 2014
Rush University Medical CenterResidency, Internal Medicine/Pediatrics, 2007 - 2011
University of Puerto Rico School of MedicineClass of 2007
Certifications & Licensure
OH State Medical License 2014 - 2026
DC State Medical License 2015 - 2024
OR State Medical License 2012 - 2015
IL State Medical License 2010 - 2011- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Start of enrollment: 2022 Oct 06
Roles: Contact, Principal Investigator
- Conditioning SCID Infants Diagnosed Early Start of enrollment: 2018 Oct 22
Roles: Principal Investigator, Contact
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) Start of enrollment: 2023 Jan 25
Roles: Contact
Publications & Presentations
PubMed
- 16 citationsComparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disordersRebecca A. Marsh, Kyle Hebert, Soyoung Kim, Christopher C. Dvorak, Victor M. Aquino
The Journal of Allergy and Clinical Immunology. 2021-08-08 - 12 citationsMevalonic aciduria: Does stem cell transplant fully cure disease?Ann Marie Szymanski, Blachy J. Dávila Saldaña, Carlos R. Ferreira, Brett Loechelt, Lawrence Jung
Pediatric Transplantation. 2020-02-01 - 69 citationsExcellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC reportLauri Burroughs, Aleksandra Petrovic, Ruta Brazauskas, Xuerong Liu, Linda M. Griffith
Blood. 2020-06-04
Journal Articles
- Activated phosphoinositide 3-kinase δ syndrome in a patient with a former diagnosis of common variable immune deficiency, bronchiectasis, and lymphoproliferative disease.Kannan JA, Dávila-Saldaña BJ, Zhang K, Filipovich AH, Kucuk ZY., Ann Allergy Asthma Immunol., 9/11/2015
Other Languages
- Italian, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
